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With great interest I have read the article from Mauro Biffi
about ICD programming (Biffi M. ICD programming. Indian
Heart J. 2014 JanuaryeFebruary; 66S1:S88eS100). I'm delighted
that finally there is a current review on this subject published.
I have just some comments on this review:
1) In the present review, the author mentioned the MADIT-
RIT trial as following “Indeed, whereas inappropriate
shock delivery was significantly reduced in both the
RELEVANT and in the ADVANCE III study, no effect was
observed in the MADIT-RIT trial, possibly owing to the
absence of SVT discriminators in the VF zone in Boston
Scientific devices. Indeed, inappropriate ATP delivery on
AF or SVTs inducing VT/VF was hypothesized as a possible
explanation of ATP being associated with increased mor-
tality in the MADIT-RIT trial8,9”. The author might have
mixed up the existing letters to the editor in the N Engl J
Med about the MADIT-RIT trial (see author's reference 9)
since not “Kay GN, Ellenbogen KA. A clinical trial of ICD
programming. N Engl J Med. 2013 Mar 7; 368(10):965” but
“Reif S, Antoni D, Hoffmann E. A clinical trial of ICD pro-
gramming. N Engl J Med. 2013 Mar 7; 368(10):964” have
discussed the subject “inappropriate ATP delivery on AF or
SVTs inducing VT/VF was hypothesized as a possible
explanation of ATP being associated with increased mor-
tality in theMADIT-RIT trial”. This should be adapted in the
final version of this review.
2) Why doesn't the author enable SMART Mode in Medtronic
devices or equivalent ATP optimization features in other
devices (Fig. 3)? Is there any disadvantage to be considered
for the author? A short discussion about this would be
interesting.
3) The author states in the paragraph on SVT discrimination
that “Arrhythmia discrimination is applied at VT detection(VF also for Medtronic and NayaMed), whereas it is not
applied during re-detection (after the first therapy has been
delivered) apart from Medtronic, NayaMed, and Boston
Scientific, that can apply “stability” during re-detection. “I
agree with the fact that “stability” is the only optional
feature for re-detection in Medtronic devices with
concomitant limitation in SVT specificity. Therefore, I was
wondering why the author has disabled the “stability”
feature in Fig. 2. Would the author recommend to disable
this feature for re-detection?
4) In contrast to the author's statement from above, there are
in fact devices e.g. from Sorin and Biotronik, respectively
where dual chamber SVT discrimination algorithms (PAR-
ADþ and SMART, respectively) work not only during
detection but also during re-detection. This might have an
impact on SVT discrimination and the rate of inappropriate
ICD therapy and should be taken into account.
I am interested in your opinion on these remarks. Thanks
verymuch in anticipation of your work and cooperation, and I
look forward to hearing from you soon.
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